Compare Stocks: PLX, GLUE, IMTX, and SNDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$10.31 -1.8%	$11.50	$9.68 ▼ $25.77	$880.99M	1.4	1.41 million shs	1.26 million shs
IMTX Immatics	$6.69 +4.2%	$7.83	$6.09 ▼ $12.41	$877.55M	1.38	1.20 million shs	964,299 shs
PLX Protalix BioTherapeutics	$3.13 +9.4%	$2.67	$1.65 ▼ $3.19	$230.44M	0.01	911,516 shs	3.09 million shs
SNDX Syndax Pharmaceuticals	$9.59 +1.1%	$15.72	$9.15 ▼ $25.59	$854.37M	0.48	3.91 million shs	4.36 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-1.81%	-4.55%	-2.00%	-34.91%	-28.00%
IMTX Immatics	+4.21%	-3.18%	-7.21%	-30.24%	-27.20%
PLX Protalix BioTherapeutics	+9.44%	+16.36%	+12.59%	+32.63%	+46.95%
SNDX Syndax Pharmaceuticals	+1.05%	-8.23%	-42.05%	-49.74%	-45.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$10.31 -1.8%	$11.50	$9.68 ▼ $25.77	$880.99M	1.4	1.41 million shs	1.26 million shs
IMTX Immatics	$6.69 +4.2%	$7.83	$6.09 ▼ $12.41	$877.55M	1.38	1.20 million shs	964,299 shs
PLX Protalix BioTherapeutics	$3.13 +9.4%	$2.67	$1.65 ▼ $3.19	$230.44M	0.01	911,516 shs	3.09 million shs
SNDX Syndax Pharmaceuticals	$9.59 +1.1%	$15.72	$9.15 ▼ $25.59	$854.37M	0.48	3.91 million shs	4.36 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-1.81%	-4.55%	-2.00%	-34.91%	-28.00%
IMTX Immatics	+4.21%	-3.18%	-7.21%	-30.24%	-27.20%
PLX Protalix BioTherapeutics	+9.44%	+16.36%	+12.59%	+32.63%	+46.95%
SNDX Syndax Pharmaceuticals	+1.05%	-8.23%	-42.05%	-49.74%	-45.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.75	Moderate Buy	$26.44	156.49% Upside
IMTX Immatics	2.75	Moderate Buy	$19.00	184.01% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	283.39% Upside
SNDX Syndax Pharmaceuticals	2.82	Moderate Buy	$41.60	333.79% Upside

Current Analyst Ratings Breakdown

Latest PLX, GLUE, IMTX, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/6/2026	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$27.00 ➝ $25.00
11/4/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
11/3/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
11/3/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$38.00 ➝ $36.00
11/3/2026	SNDX Syndax Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$43.00
10/29/2026	IMTX Immatics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$21.00
10/19/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/13/2026	IMTX Immatics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$15.00
10/13/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$38.00
10/11/2026	GLUE Monte Rosa Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$17.00 ➝ $19.00
10/11/2026	GLUE Monte Rosa Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold

(Data available from 11/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$70.33M	12.53	N/A	N/A	$5.81 per share	1.77
IMTX Immatics	$43.44M	21.05	N/A	N/A	$4.09 per share	1.64
PLX Protalix BioTherapeutics	$84.69M	2.98	$0.18 per share	17.80	$0.47 per share	6.66
SNDX Syndax Pharmaceuticals	$172.35M	5.01	N/A	N/A	($0.19) per share	-50.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.40	N/A	N/A	N/A	-186.24%	-30.14%	-20.35%	N/A
IMTX Immatics	-$222.26M	-$1.95	N/A	N/A	N/A	-533.26%	-52.27%	-43.99%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.25	N/A	10.10	N/A	-21.03%	-30.89%	-11.74%	N/A
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.36	N/A	N/A	N/A	-72.32%	-804.38%	-34.93%	N/A

Latest PLX, GLUE, IMTX, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	IMTX Immatics	-$0.5119	-$0.58	-$0.0681	-$0.57	$12.18 million	$7.84 million
11/5/2026	Q3 2026	GLUE Monte Rosa Therapeutics	-$0.2145	$0.03	+$0.2445	$0.03	$33.87 million	$54.37 million
11/2/2026	Q3 2026	SNDX Syndax Pharmaceuticals	-$0.5041	-$0.55	-$0.0459	-$0.55	$81.38 million	$83.30 million
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	10.32	10.32
IMTX Immatics	N/A	7.54	7.54
PLX Protalix BioTherapeutics	N/A	1.98	1.27
SNDX Syndax Pharmaceuticals	38.95	4.69	4.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
IMTX Immatics	64.41%
PLX Protalix BioTherapeutics	16.53%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.40%
IMTX Immatics	3.30%
PLX Protalix BioTherapeutics	6.70%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	173	85.45 million	79.98 million	Optionable
IMTX Immatics	704	136.69 million	132.18 million	Optionable
PLX Protalix BioTherapeutics	226	80.57 million	69.00 million	Optionable
SNDX Syndax Pharmaceuticals	298	90.03 million	85.71 million	Optionable

PLX, GLUE, IMTX, and SNDX Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

November 10 at 6:16 PM | globenewswire.com

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

November 9 at 5:26 PM | globenewswire.com

CenterBook Partners LP Makes New $5.14 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX

November 7, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SNDX FY2026 Earnings?

November 7, 2026 | americanbankingnews.com

Syndax Pharmaceuticals stock: ASH to feature 19 drug abstracts

November 5, 2026 | ad-hoc-news.deA

Why Is Syndax Pharmaceuticals (SNDX) Drawing So Much ASH 2026 Attention?

November 5, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

November 5, 2026 | prnewswire.com

HC Wainwright Has Positive Forecast for SNDX FY2026 Earnings

November 5, 2026 | marketbeat.com

Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key

November 5, 2026 | seekingalpha.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - November 4, 2026

November 5, 2026 | biospace.comB

Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week Low - Here's What Happened

November 4, 2026 | marketbeat.com

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

November 4, 2026 | globenewswire.com

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

November 4, 2026 | globenewswire.com

Syndax Announces CFO Transition - Aaron A. Ondrey Appointed Chief Financial Officer

November 4, 2026 | finviz.comF

Syndax Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation

November 4, 2026 | seekingalpha.com

Syndax Pharmaceuticals Stock Gains Focus After Revenue Growth And Pipeline Progress

November 3, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

November 3, 2026 | globenewswire.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 9.7% - Still a Buy?

November 3, 2026 | marketbeat.com

Syndax Pharmaceuticals, Inc. Announces CFO Changes

November 3, 2026 | marketscreener.comM

Syndax Pharmaceuticals (SNDX) Stock May Be Rich After Revuforj Award Win

November 3, 2026 | finance.yahoo.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Has Consensus Price Target of $41.80 According to Brokerages

November 3, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, GLUE, IMTX, and SNDX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$10.31 -0.19 (-1.81%)

Closing price 11/11/2026 04:00 PM Eastern

Extended Trading

$10.33 +0.02 (+0.19%)

As of 08:29 AM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Immatics NASDAQ:IMTX

$6.69 +0.27 (+4.21%)

Closing price 11/11/2026 04:00 PM Eastern

Extended Trading

$6.98 +0.28 (+4.26%)

As of 08:28 AM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Protalix BioTherapeutics NYSE:PLX

$3.13 +0.27 (+9.44%)

Closing price 11/11/2026 04:00 PM Eastern

Extended Trading

$3.05 -0.08 (-2.56%)

As of 08:34 AM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.59 +0.10 (+1.05%)

As of 11/11/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, GLUE, IMTX, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, GLUE, IMTX, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, GLUE, IMTX, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, GLUE, IMTX, and SNDX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Immatics NASDAQ:IMTX

Protalix BioTherapeutics NYSE:PLX

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, GLUE, IMTX, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, GLUE, IMTX, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, GLUE, IMTX, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, GLUE, IMTX, and SNDX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Immatics NASDAQ:IMTX

Protalix BioTherapeutics NYSE:PLX

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools